123 related articles for article (PubMed ID: 36754853)
1. Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
Parimi V; Choi W; Feng M; Fong M; Hoffman-Censits J; Kates M; Lombardo KA; Comperat E; McConkey DJ; Hahn NM; Esteves RS; Matoso A
Histopathology; 2023 Jun; 82(7):991-1002. PubMed ID: 36754853
[TBL] [Abstract][Full Text] [Related]
2. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
3. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of early stage small cell bladder cancer is not always dismal.
Lim JH; Sundar S
ESMO Open; 2019; 4(6):e000559. PubMed ID: 31798978
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology.
Lin J; Whalen M; Holder D; Hruby G; Decastro GJ; McKiernan J
Can J Urol; 2013 Apr; 20(2):6690-5. PubMed ID: 23587508
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Teo MY; Guercio BJ; Arora A; Hao X; Regazzi AM; Donahue T; Herr HW; Goh AC; Cha EK; Pietzak E; Donat SM; Dalbagni G; Bochner BH; Olgac S; Sarungbam J; Sirintrapun SJ; Chen YB; Gopalan A; Fine SW; Tickoo SK; Reuter VE; Weigelt B; Schultheis AM; Funt SA; Bajorin DF; Solit DB; Iyer G; Ostrovnaya I; Rosenberg JE; Al-Ahmadie H
Clin Genitourin Cancer; 2022 Oct; 20(5):431-441. PubMed ID: 35676169
[TBL] [Abstract][Full Text] [Related]
10. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
Granfors T; Tomic R; Ljungberg B
Scand J Urol Nephrol; 2009; 43(4):293-9. PubMed ID: 19363744
[TBL] [Abstract][Full Text] [Related]
11. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S
J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657
[TBL] [Abstract][Full Text] [Related]
12. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW
Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
14. [The prognostic value of adjuvant and neoadjuvant chemotherapy in total cystectomy for locally advanced bladder cancer].
Habuchi T; Kakehi Y; Terachi T; Ogawa O; Yoshida O
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):809-17. PubMed ID: 10565159
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
16. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
17. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder.
Kaushik D; Frank I; Boorjian SA; Cheville JC; Eisenberg MS; Thapa P; Tarrell RF; Thompson RH
Int J Urol; 2015 Jun; 22(6):549-54. PubMed ID: 25761779
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
20. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
